ROS1 rearrangement in advanced NSCLC: entrectinib (CNS-active) and crizotinib have establ...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-ROS1-FUSION-NSCLC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-ROS1-FUSION |
|---|---|
| Variant | fusion (gene-level, TKI-naive) |
| Disease | DIS-NSCLC |
| ESCAT tier | IA |
| Recommended combinations | repotrectinib monotherapy (preferred 1L), entrectinib monotherapy (1L, CNS-active), crizotinib monotherapy (1L alternative, less CNS activity) |
| Evidence summary | ROS1 rearrangement in advanced NSCLC: entrectinib (CNS-active) and crizotinib have established 1L approvals. Repotrectinib (TRIDENT-1, Drilon 2024) demonstrated superior PFS and CNS activity 1L — including activity vs G2032R resistance — and is increasingly preferred. Lorlatinib also active off-label. |
Notes
ESCAT IA. OncoKB Level 1. ~1-2% NSCLC adenocarcinoma. RNA-NGS preferred for fusion detection; FISH and IHC alternatives.
Used By
No reverse references found in the YAML corpus.